Looking for the Achilles heel of atheromatosis: could it be immunotherapy?

References

• 1. Papoutsis K, Kapelouzou A, Georgiopoulos G et al. Tissue-specific relaxin-2 is differentially associated with the presence/size of an arterial aneurysm and the severity of atherosclerotic disease in humans. Acta Pharmacol. Sin. doi:10.1038/s41401-019-0350-5 (2020) (Epub ahead of print).
  MedlineGoogle Scholar
• 2. Ridker PM, Everett BM, Thuren T et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377(12), 1119–1131 (2017).
  Medline CASGoogle Scholar
• 3. Ridker PM, Macfadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 391(10118), 319–328 (2018).
  Medline CASGoogle Scholar
• 4. Ridker PM, Macfadyen JG, Glynn RJ et al. Inhibition of interleukin-1beta by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J. Am. Coll. Cardiol. 71(21), 2405–2414 (2018).
  Medline CASGoogle Scholar
• 5. Ravelli RB, Gigant B, Curmi PA et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428(6979), 198–202 (2004).
  Medline CASGoogle Scholar
• 6. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 61(4), 404–410 (2013).
  Medline CASGoogle Scholar
• 7. Tardif JC, Kouz S, Waters DD et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381(26), 2497–2505 (2019).
  Medline CASGoogle Scholar
• 8. Fuster JJ, Maclauchlan S, Zuriaga MA et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355(6327), 842–847 (2017).
  Medline CASGoogle Scholar
• 9. Mallat Z, Corbaz A, Scoazec A et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104(14), 1598–1603 (2001).
  Medline CASGoogle Scholar
• 10. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4(12), 977–987 (2005).
  Medline CASGoogle Scholar
• 11. Ii M, Losordo DW. Statins and the endothelium. Vascul. Pharmacol. 46(1), 1–9 (2007).
  Medline CASGoogle Scholar
• 12. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J. Exp. Med. 200(1), 69–78 (2004).
  Medline CASGoogle Scholar
• 13. De Haro J, Bleda S, Laime IV, Carballido B, Uyaguari J, Acin F. Aspirin-dependent platelet inflammatory inhibition in healthy subjects decreases NLRP-1 inflammasome. Ann. Vasc. Surg. 59, 244–247 (2019).
  MedlineGoogle Scholar
• 14. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336(14), 973–979 (1997).
  Medline CASGoogle Scholar
• 15. Thomas MR, Storey RF. Effect of P2Y12 inhibitors on inflammation and immunity. Thromb. Haemost. 114(3), 490–497 (2015).
  MedlineGoogle Scholar
• 16. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
  Medline CASGoogle Scholar
• 17. Ridker PM, Everett BM, Pradhan A et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380(8), 752–762 (2019).
  Medline CASGoogle Scholar
• 18. Tardif JC, Mcmurray JJ, Klug E et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 371(9626), 1761–1768 (2008).
  Medline CASGoogle Scholar
• 19. Nicholls SJ, Kastelein JJ, Schwartz GG et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 311(3), 252–262 (2014).
  Medline CASGoogle Scholar
• 20. O'donoghue ML, Braunwald E, White HD et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 312(10), 1006–1015 (2014).
  MedlineGoogle Scholar
• 21. Tardif JC, Tanguay JF, Wright SR et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J. Am. Coll. Cardiol. 61(20), 2048–2055 (2013).
  Medline CASGoogle Scholar
• 22. Abbate A, Van Tassell BW, Biondi-Zoccai G et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am. J. Cardiol. 111(10), 1394–1400 (2013).
  Medline CASGoogle Scholar
• 23. El Sayed H, Kerensky R, Stecher M, Mohanty P, Davies M. A randomized Phase II study of Xilonix, a targeted therapy against interleukin 1alpha, for the prevention of superficial femoral artery restenosis after percutaneous revascularization. J. Vasc. Surg. 63(1), 133–141.e1 (2016).
  MedlineGoogle Scholar
• 24. Gaztanaga J, Farkouh M, Rudd JH et al. A Phase II randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome. Atherosclerosis 240(1), 53–60 (2015).
  Medline CASGoogle Scholar
• 25. O'donoghue ML, Glaser R, Cavender MA et al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a randomized clinical trial. JAMA 315(15), 1591–1599 (2016).
  MedlineGoogle Scholar